Sinopharm-group pharma distributor and manufacturer serving Guangdong and South China's hospitals and pharmacies.
Sinopharm-group pharma distributor and manufacturer serving Guangdong and South China's hospitals and pharmacies.
Earns a small margin on each drug it buys from manufacturers and delivers to hospitals and pharmacies, so revenue is large relative to profit. Sinopharm, the state-owned national drug distributor, is its controlling shareholder.
In one line: A regional McKesson with a small factory arm.
Moat: narrow (scale, distribution). Dense South China distribution network under state-owned Sinopharm's national logistics umbrella.
Headquarters: Shenzhen, China · Employees: 28,336
Size China National Accord Medicines (000028.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.81B, the 1270th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥21.24 on 18 Nov 2026.
Performance Over six months the shares fell 3.2%, against -10.4% for the median peer and -20.0% for the China market (cap-weighted) — 9th highest of 21 in its peer set.
Growth Revenue grew 0.4% over the last twelve months (peer median +10.0%); the operating margin is 2.3% (peer median 14.4%).
Valuation It trades at 10.8× forward earnings against a peer median of 20.4× (2nd cheapest of 19).
Price implies For today's price to make sense, revenue must grow about -10% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is -14 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 1.4 points above its cost of capital (5.0% WACC).
Next results Next results expected around 14 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥73.4B | CN¥73.3B | CN¥74.3B | CN¥75.4B | CN¥73.3B |
| Revenue growth | — | -1% | -1% | +3% | — |
| Gross profit | CN¥7.68B | CN¥6.36B | CN¥6.46B | CN¥7.40B | CN¥7.38B |
| EBITDA | n/a | CN¥3.14B | CN¥3.25B | CN¥3.92B | CN¥3.79B |
| Net income | CN¥1.13B | CN¥1.14B | CN¥642M | CN¥1.60B | CN¥1.49B |
| Free cash flow | CN¥1.50B | CN¥1.52B | CN¥3.18B | CN¥2.85B | CN¥2.21B |
| Capital expenditure | CN¥139M | CN¥217M | CN¥283M | CN¥322M | CN¥322M |
| Total debt | CN¥12.0B | CN¥14.7B | CN¥14.3B | CN¥13.8B | CN¥10.6B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| China National Accord Medicines 000028.SZ | $1.81B | -3% | 0% | 2% | 10.8× | -9.5% |
| China Resources Pharmaceutical 3320.HK | $3.60B | -7% | +8% | 4% | 5.8× | -4.9% |
| Shanghai Pharmaceuticals 601607.SS | $8.23B | 0% | +4% | 3% | 11.2× | -10.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 000028.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +5.5% | +0.1% | 5th highest of 21 |
| 6-month return | -3.2% | -10.4% | 9th highest of 21 |
| Distance from 52-week high | -14.8% | -32.8% | 3rd highest of 21 |
| Revenue growth (TTM) | +0.4% | +10.0% | 6th lowest of 21 |
| Operating margin | 2.3% | 14.4% | 5th lowest of 21 |
| Forward P/E | 10.8× | 20.4× | 2nd cheapest of 19 |
| Growth the price implies (Req g, 7 yrs) | -9.5% | 6.7% | least demanding of 15 |
| Growth delivered (Del g) | +4.2% | +8.1% | 3rd lowest of 15 |
| Hurdle (Req g minus delivered) | -13.8 pp | -3.9 pp | 4th least demanding of 15 |
| ROIC minus cost of capital | +1.4 pp | +0.9 pp | 11th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| China National Accord Medicines 000028.SZ | China | $1.81B | -3% | 0% | 2% | 10.8× | -9.5% | +4.2% |
| Zymeworks ZYME | United States | $1.81B | +5% | +98% | 17% | 160.4× | n/a | n/a |
| Ultragenyx Pharmaceutical RARE | United States | $1.81B | -24% | +16% | -64% | 9.6× | n/a | n/a |
| Qingdao Baheal Medical 301015.SZ | China | $1.81B | +2% | -6% | 8% | 21.0× | 10.1% | +5.0% |
| Shenzhen Hepalink Pharmaceutical 002399.SZ | China | $1.80B | -12% | -6% | 8% | 25.8× | -0.7% | +0.5% |
| Guobang Pharma 605507.SS | China | $1.82B | -6% | +3% | 12% | 15.7× | -6.0% | +7.4% |
| United Laboratories International 3933.HK | Hong Kong | $1.80B | -20% | -13% | 5% | 13.0× | 1.2% | +7.8% |
| Shenyang Xingqi Pharmaceutical 300573.SZ | China | $1.83B | -25% | +17% | 33% | 13.0× | 5.4% | +29.1% |
| Eton Pharmaceuticals ETON | United States | $1.79B | +226% | +101% | 29% | 24.6× | 21.9% | +359.6% |
| Harbin Pharmaceutical 600664.SS | China | $1.78B | +32% | +2% | 5% | 19.7× | -5.3% | +8.2% |
| Dermapharm DMP.DE | Germany | $1.85B | -29% | +2% | 21% | 13.2× | -3.4% | +8.0% |
| CSPC Hunan Jingfeng Pharmaceutical 000908.SZ | China | $1.85B | -38% | +5% | -18% | n/a | n/a | n/a |
| Agios Pharmaceuticals AGIO | United States | $1.78B | +4% | +214% | -298% | n/a | n/a | n/a |
| Cohance Lifesciences COHANCE.NS | India | $1.87B | +7% | +14% | 2% | 96.3× | n/a | n/a |
| Tibet Rhodiola Pharmaceutical 600211.SS | China | $1.87B | -8% | +13% | 27% | 12.5× | -1.2% | +16.7% |
| Anhui Anke Biotechnology (Group) 300009.SZ | China | $1.88B | -12% | -9% | 30% | 18.1× | 8.0% | +9.3% |
| Pfizer PFIZER.NS | India | $1.88B | -20% | +12% | 34% | 21.9× | 11.2% | +2.4% |
| Alivus Life Sciences ALIVUS.NS | India | $1.90B | +36% | +8% | 31% | 23.8× | 20.1% | +6.2% |
| NATCO Pharma NATCOPHARM.NS | India | $1.73B | -27% | -30% | 17% | 19.1× | 20.5% | +19.0% |
| Shilpa Medicare SHILPAMED.NS | India | $1.91B | +94% | +37% | 21% | 54.3× | n/a | n/a |
| BrightGene Bio-Medical Technology 688166.SS | China | $1.71B | -57% | +14% | 7% | 74.9× | 35.3% | +9.2% |